Search results for "Fluorescein angiography"

showing 10 items of 65 documents

OPTICAL COHERENCE TOMOGRAPHIC FINDINGS IN BIETTI’S CRYSTALLINE TAPETORETINAL DYSTROPHY

2014

Purpose: To report the optical coherence tomography (OCT) findings of Bietti crystalline tapetoretinal dystrophy. Design: Observational case report. Methods: A subject with Bietti crystalline tapetoretinal dystrophy was evaluated with ophthalmoscopy, fluorescein angiography, and OCT (Stratus). Results: OCT showed thinning and hyporeflectivity of the outer nuclear layer in the macula due to photoreceptor degeneration. The retinal areas showing atrophy of the retinal pigment epithelium displayed greater penetration of the optical beam into the choroid and visualization of residual choroidal vessels. The hyperreflective band normally seen under the neurosensory retina was extremely wide when a…

Retinamedicine.medical_specialtyRetinal pigment epitheliumgenetic structuresmedicine.diagnostic_testbusiness.industryRetinalGeneral MedicineFluorescein angiographyeye diseasesOphthalmoscopyOphthalmologychemistry.chemical_compoundmedicine.anatomical_structureOptical coherence tomographychemistryOphthalmologymedicinesense organsChoroidbusinessOuter nuclear layerRETINAL Cases & Brief Reports
researchProduct

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections

2022

Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD), evaluated by optical coherence tomography angiography (OCTA). Materials and Methods: This is a bicentric retrospective case series. Patients with newly diagnosed type 3 MNV treated with brolucizumab IVI and at least 6 months follow-up were enrolled. OCTA en face images and B-scans were analyzed for lesions at baseline, 1 m…

Vascular Endothelial Growth Factor Atype 3 neovascularization.brolucizumabNeovascularization PathologicVisual Acuityneovascular age-related macular degeneration; type 3 neovascularization; retinal angiomatous proliferation; brolucizumab; optical coherence tomography angiography; intravitreal injectionintravitreal injectionretinal angiomatous proliferationEndothelial Growth Factorsneovascular age-related macular degenerationGeneral MedicineAntibodies Monoclonal Humanizedoptical coherence tomography angiographyIntravitreal InjectionsHumansFluorescein AngiographyTomography Optical CoherenceRetrospective StudiesMedicina
researchProduct

Macular edema: Miscellaneous.

2010

International audience; Abstract. This article provides the reader with practical information to be applied to the various remaining causes of macular edema. Some macular edemas linked to ocular diseases like radiotherapy after ocular melanomas remained of poor functional prognosis due to the primary disease. On the contrary, macular edemas occurring after retinal detachment or after some systemic or local treatment use are often temporary. Macular edema associated with epiretinal membranes or vitreomacular traction is the main cause of poor functional recovery. However, the delay to observe a significant improvement of vision after surgery should be long, as usually observed in tractional …

medicine.medical_specialtyEye Diseasesgenetic structuresVitreomacular tractionPrimary diseaseTreatment useMacular EdemaHemangiomaOphthalmologyProstaglandins SyntheticmedicineHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansMacular edemaRadiotherapymedicine.diagnostic_testbusiness.industryRetinal detachmentGeneral MedicineFunctional recoverymedicine.diseaseFluorescein angiographyeye diseasesOphthalmology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory Organssense organsOphthalmic Solutionsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Intravitreal dexamethasone implant for cystoid macular edema and inflammation after scleral buckling

2015

Purpose Cystoid macular edema may occur following scleral buckling and therefore deteriorate the visual outcome. Inflammation may be the major causative factor in the development of postoperative cystoid macular edema. This case demonstrates the effectiveness of a dexamethasone implant as a treatment after the onset of choroidal inflammation and cystoid macular edema 6 months following scleral buckling and having visual acuity restored. Methods A 59-year-old phakic woman treated with scleral buckling for macula-off retinal detachment presented 2 months after surgery with cystoid macular edema with choroidal inflammation. Optical coherence tomography and fluorescein angiography were performe…

medicine.medical_specialtyTriamcinolone acetonideVisual acuityChoroiditisgenetic structuresVisual AcuityTriamcinolone AcetonideDrug ImplantDexamethasoneMacular EdemaChoroiditiPostoperative ComplicationsGlucocorticoidOptical coherence tomographyOphthalmologyChoroidal inflammationMedicineHumansFluorescein AngiographyMacular edemaGlucocorticoidsDexamethasoneDrug Implantsmedicine.diagnostic_testbusiness.industryIntravitreal InjectionRetinal DetachmentRetinal detachmentGeneral MedicineIntravitreal dexamethasone implantMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesOphthalmologyScleral BucklingIntravitreal InjectionsFemalesense organsImplantPostoperative Complicationmedicine.symptombusinessCystoid macular edemaTomography Optical Coherencemedicine.drugHuman
researchProduct

Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment

2012

Abstract Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year followup. There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGF agents to treat this condition. A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmic history of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmic examination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudati…

medicine.medical_specialtyVisual acuitygenetic structuresPegaptanibIntravitreal pegaptanibCentral retinal vein occlusionOphthalmologymedicinePegaptanib SodiumExudative macular detachment; Central retinal vein occlusion; Intravitreal pegaptanibMedical historyMacular edemamedicine.diagnostic_testSettore MED/30 - Malattie Apparato Visivobusiness.industryCentral retinal vein occlusionExudative macular detachmentmedicine.diseaseFluorescein angiographyeye diseasesSurgerysense organsmedicine.symptomRanibizumabbusinessmedicine.drugJournal of Clinical & Experimental Ophthalmology
researchProduct

Morphologische und funktionelle Ergebnisse nach transpupillarer Thermotherapie (TTT) maligner Aderhautmelanome

2006

BACKGROUND The aim of this study was to evaluate the course of tumor regression and visual impairment in choroidal melanomas treated by transpupillary thermotherapy (TTT) alone. PATIENTS AND METHODS In a prospective, non-randomized analysis 26 patients suffering from primary choroidal melanoma (posterior to the equator with base < or = 12 and thickness < or = 4.5 mm) were treated with the TTT standard protocol and followed for 33 - 45 months. Fluorescein and ICG angiographies were performed initially and after tumor regression clinically. RESULTS 22 tumors were significantly flattened after 1 - 3 TTT sessions. 4 tumors required additional therapy with ruthenium plaque. Visual acuity remaine…

medicine.medical_specialtyVisual acuitygenetic structuresmedicine.diagnostic_testbusiness.industryFluorescein angiographymedicine.diseaseeye diseasesSurgeryOphthalmologychemistry.chemical_compoundChoroidal neovascularizationchemistryOphthalmologyAngiographymedicinesense organsFluoresceinmedicine.symptomProspective cohort studybusinessIndocyanine greenMacular edemaKlinische Monatsblätter für Augenheilkunde
researchProduct

Acquired Ocular Toxoplasmosis

1991

A 31-year-old man exhibited a bilateral deterioration of vision over the course of 1 week. The right fundus showed the picture of a central vein occlusion, and the left of a disseminated choroiditis. Indirect immunofluorescent testing indicated a titer of 1:2048 for toxoplasmosis. Fluorescein angiography revealed a hitherto unique picture of isolated choroidal occlusions but neither a central vein occlusion nor a disseminated choroiditis. Using only specific antitoxoplasmotic therapy, the patient regained full visual acuity on both sides. The original findings and the results of a 14-year follow-up are presented.

medicine.medical_specialtyVisual acuitymedicine.diagnostic_testbusiness.industryEye diseaseFundus (eye)Fluorescein angiographymedicine.diseaseeye diseasesVein occlusionToxoplasmosisSurgeryOphthalmologychemistry.chemical_compoundchemistryOphthalmologyAngiographymedicinesense organsFluoresceinmedicine.symptombusinessOphthalmology
researchProduct

Evolving European guidance on the medical management of neovascular age related macular degeneration

2006

BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. METHODS: Consensus from a round table of European retina specialists was obt…

medicine.medical_specialtygenetic structuresBevacizumabAntibodies Monoclonal HumanizedTriamcinolone AcetonideMacular DegenerationCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansPregnadienediolsEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryAntibodies MonoclonalAptamers NucleotideMacular degenerationFluorescein angiographymedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesSensory SystemsOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyPerspectivesense organsAnecortave acetateChoroidRanibizumabmedicine.symptombusinessmedicine.drugBritish Journal of Ophthalmology
researchProduct

Macular laser photocoagulation guided by spectral-domain optical coherence tomography versus fluorescein angiography for diabetic macular edema.

2011

Roberto Gallego-Pinazo1,2, Ana Marina Suelves-Cogollos1, Rosa Dolz-Marco1, J Fernando Arevalo3, Salvador Garc&amp;iacute;a-Delpech1, J Luis Mullor4, Manuel D&amp;iacute;az-Llopis1,2,51Department of Ophthalmology, Hospital Universitario La Fe, Valencia, Spain; 2Centro de Investigaci&amp;oacute;n Biom&amp;eacute;dica en Red de Enfermedades Raras, Valencia, Spain; 3Retina and Vitreous Service, Clinical Ophthalmology Center, Caracas, Venezuela; 4Unit of Experimental Ophthalmology, Hospital Universitario La Fe, Valencia, Spain; 5University of Valencia, Faculty of Medicine, Valencia, SpainBackground: The aim of this study was to compare the efficacy of spectral-domain optical coherence tomography…

medicine.medical_specialtygenetic structuresmedicine.diagnostic_testbusiness.industryDiabetic macular edemaClinical OphthalmologySpectral domainFluorescein angiographyLasereye diseaseslaw.inventionOphthalmologyOptical coherence tomographymacular laser photocoagulationlawspectral-domain optical coherence tomographyfluorescein angiographyOphthalmologymedicinesense organsdiabetic macular edemabusinessOriginal Research
researchProduct

Classic Choroidal Neovascularization

2009

Since Donald Gass’s pioneering work in 1967, which demonstrated the role of choroidal neovascularization (CNV) in wet (exudative) AMD, visible (classic) CNV, well demarcated and well-defined on fluorescein angiography, has become the most characteristic form of AMD.

medicine.medical_specialtygenetic structuresmedicine.diagnostic_testbusiness.industryFluorescein angiographyeye diseasesmedicine.anatomical_structureChoroidal neovascularizationOphthalmologymedicinesense organsmedicine.symptomOuter nuclear layerbusiness
researchProduct